Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel

PURPOSE: We evaluated the relationship between prostate-specific antigen (PSA) and overall survival in the context of a prospectively randomized clinical trial comparing androgen-deprivation therapy (ADT) plus docetaxel with ADT alone for initial metastatic hormone-sensitive prostate cancer. METHODS...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Harshman, Lauren C., Chen, Yu-Hui, Liu, Glenn, Carducci, Michael A., Jarrard, David, Dreicer, Robert, Hahn, Noah, Garcia, Jorge A., Hussain, Maha, Shevrin, Daniel, Eisenberger, Mario, Kohli, Manish, Plimack, Elizabeth R., Cooney, Matthew, Vogelzang, Nicholas J., Picus, Joel, Dipaola, Robert, Sweeney, Christopher J.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805480/
https://ncbi.nlm.nih.gov/pubmed/29261442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.75.3921
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares